Rakuten Medical, Inc. is a global biotechnology company founded in 2010, dedicated to developing and commercializing precision cell-targeting therapies through our proprietary Alluminox™ platform. Our innovative technology is centered around photoimmunotherapy, developed by Dr. Hisataka Kobayashi at the National Cancer Institute. Our lead product, ASP-1929, is an antibody-dye conjugate designed to selectively target and treat various solid tumors, including head and neck cancers, by utilizing the epidermal growth factor receptor (EGFR). ASP-1929 has received Fast Track designation from the U.S. FDA and is currently undergoing a global Phase 3 clinical trial for recurrent head and neck cancer. We are committed to advancing our Alluminox™ platform to address multiple cancer indications and are actively seeking collaborations and investments to expand our pipeline.